Militia Capital Partners LP Takes Position in Harrow, Inc. $HROW

Militia Capital Partners LP acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 47,000 shares of the company’s stock, valued at approximately $2,303,000. Harrow makes up about 0.9% of Militia Capital Partners LP’s investment portfolio, making the stock its 28th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Harrow during the fourth quarter valued at approximately $26,000. Raymond James Financial Inc. bought a new stake in shares of Harrow during the second quarter valued at approximately $48,000. SBI Securities Co. Ltd. raised its position in shares of Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. William Blair reiterated an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. Wall Street Zen cut shares of Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a research report on Friday, April 3rd. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $69.43.

Insiders Place Their Bets

In other news, Director Adrienne L. Graves acquired 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were acquired at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company’s stock, valued at approximately $31,070. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew R. Boll acquired 3,500 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the transaction, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. The trade was a 0.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.80% of the company’s stock.

Harrow Trading Down 1.4%

HROW stock opened at $38.40 on Wednesday. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a twelve month low of $28.54 and a twelve month high of $54.85. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -93.66 and a beta of 0.28. The firm’s fifty day simple moving average is $36.15 and its two-hundred day simple moving average is $41.60.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The firm had revenue of $44.20 million for the quarter, compared to the consensus estimate of $52.43 million. During the same quarter last year, the firm earned ($0.38) EPS. As a group, analysts anticipate that Harrow, Inc. will post 0.29 earnings per share for the current year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.